Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Immunext Inc. currently maintains a portfolio with 2 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. The prosecution workload is distributed across 2 distinct examiners and 2 distinct art units. This structure suggests that the company is navigating multiple regulatory pathways simultaneously, as each pending action is handled by a different examiner in a separate art unit.
The busiest examiner for this portfolio is CHANDRAKUMAR, NIZAL S, who is responsible for 1 pending office action. Because the total count of pending office actions is 2 and the busiest examiner handles 1, the workload is split among the 2 distinct examiners involved. Practitioners should note that the 2 distinct art units may apply different examination standards even within the same Biotechnology & Pharmaceuticals field.
The presence of 2 pending office actions across multiple units requires a prosecution strategy that accounts for the specific nuances of each administrative group. CHANDRAKUMAR, NIZAL S represents a portion of the company's current interaction with the patent office. The data reflects a focused but divided administrative footprint for Immunext Inc.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.3% |
| CANELLA, KAREN A | 1 | 62.2% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271106 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | CHANDRAKUMAR, NIZAL S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18271106 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | CHANDRAKUMAR, NIZAL S | — |
| 17920445 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18271106 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 17920445 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CANELLA, KAREN A | 1643 | §112DP | Non-Final OA | — | Pending | Oct 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial